Nifedipine
- Atc Codes:C08CA05
- CAS Codes:21829-25-4
- PHARMGKB ID:21829-25-4
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Adalat, Buconif, Fedip, Nifebene, Nifedipin, Nifehexal, Ospocard; Belgium: Adalat, Hypan, Nifedipine; Bulgaria: Adalat, Cordaflex, Corinfar, Korincare, Nifedipin; Cyprus: Adalat, Fenamon, Macorel, Nifelat; Czech Republic: Adalat, Cordipin, Corinfar, Nifecard; Denmark: Adalat, Hexadilat, Nifedipin; Estonia: Adalat, Cordipin, Corinfar, Nifedipin, Nifehexal, Nycopin; Finland: Adalat, Nifangin, Nifedipin; France: Adalate, Chronadalate LP, Nifedipine; Germany: Adalat, Aprical, Bukonif, Cisday, Coracten, Corinfar, Duranifin, Jedipin, Jutadilat, Longipin, Nife-CT, Nifeclair, Nifecor, Nifedipin, Nifehexal, Nifelat, Nifical, Pidilat; Greece: Adalat, Adipine, Antiblut, Glopir, Macorel, Nifedipine; Hungary: Adalat, Cordaflex, Corinfar, Fortipine; Ireland: Adalat, Cardilate, Nifed; Italy: Adalat, Amarkor, Citilat, Coral 14 Cpr Riv., Euxat, Fenidina, Nifedicor, Nifedipina, Nipin; Latvia: Cordipin, Corinfar; Lithuania: Cordipin; Malta: Adalat, Nifedipine, Nifedipress, Nifelat; Luxembourg: Adalat, Aprical, Nifehexal, Nifeslow, Slow-Nifine, Unidipin; Netherlands: Adalat, Nifedipine; Poland: Adalat, Apo-Nifed, Cordafen, Cordipin, Corinfar, Nifecard, Nifedipine, Nifehexal, Zenusin; Portugal: Adalat, Angipina, Meborilan, Nifedipina; Romania: Adalat, Epilat, Nifedipin; Slovakia: Cordipin, Corinfar; Slovenia: Adalat, Cordipin, Nifecard; Spain: Adalat, Nifedipino; Sweden: Adalat; UK: Adalat, Adipine, Coracten, Nifedipress, Tensipine, Valni XL.
North America
Canada: Adalat, Apo-Nifed, Nifedipine, Nu-Nifed; USA: Adalat, Afeditab CR, Nifedipine, Procardia.
Latin America
Argentina: Adalat, Nifed Sol, Nifedel, Nifedipina; Brazil: Adalat, Cardalin, Dilaflux, Dilavax, Dipinal, Neo Fedipina, Nifadil-Nifedipina, Nifedicard, Nioxil, Normopres, Oxcord, Prodopina; Mexico: Adalat, Anhiten-A, Atenses, Cordilat-Tecnofarma, Fusepina, Gelprim, Linam, Nifar, Nifedigel, Nifedipino, Nifedipres, Nifezzard, Nifser, Noviken LP, Pidef.
Asia
Japan: Adalat, Allotop L, Alonix S, Atanaal, Atenerate, Cardioluft L, Casanmil, Cobalat L, Corinael L, Corodilate, Emaberin L, Herlat, Kepakuru-L, Kisalart L, Knoramin L, Kobanifate L, Menoprizin L, Milfadin, Nifedipine, Nifelat, Nifeslow, Nirena L, Ramitalate, Sepamit, Siopelmin-L, Towarat.
Drug combinations
Nifedipine and Acebutolol
Nifedipine and Atenolol
Nifedipine and Metoprolol
Chemistry
Nifedipine: C~17~H~18~N~2~O~6~. Mw: 346.33. (1) 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, dimethyl ester; (2) Dimethyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate. CAS-21829-25-4 (1973).
Pharmacologic Category
Calcium-Channel Blocking Agents; Dihydropyridines. (ATC-Code: C08CA05).
Mechanism of action
Inhibits calcium ions from entering «slow channels» or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing relaxation of coronary vascular smooth muscle and coronary vasodilation. Increases myocardial oxygen delivery in vasospastic angina.
Therapeutic use
Angina and hypertension. Pulmonary hypertension.
Pregnancy and lactiation implications
Use in pregnancy only when clearly needed and when benefits outweigh potential hazard to fetus. No data on crossing placenta. Hypotension, intrauterine growth retardation (probably related to maternal hypertension) reported. May exhibit tocolytic effects. Available evidence suggests safe use during pregnancy. Enters breast milk (compatible with lactation).
Unlabeled use
Contraindications
Hypersensitivity to nifedipine or any component of the formulation. Immediate release preparation for treatment of urgent or emergent hypertension. Acute myocardial infarction.
Warnings and precautions
Increased angina and/or MI occurred with initiation or dosage titration of calcium channel blockers. Symptomatic hypotension with or without syncope can rarely occur. Use of sublingual short-acting nifedipine in hypertensive emergencies and urgencies neither safe nor effective (serious adverse events (e.g. cerebrovascular ischemia, syncope, stroke, acute MI, and fetal distress) reported in relation to such use). Peripheral edema common. Reflex tachycardia may occur. Use with caution in severe aortic stenosis, in heart failure (may cause worsening of symptoms), in hepatic impairment, and in idiopathic hypertrophic subaortic stenosis. Severe hypotension may occur in patients taking immediate release nifedipine concurrently with β-blockers when undergoing coronary artery bypass graft with high-dose fentanyl anesthesia. The elderly may be more susceptible to adverse effects. Extended release formulation consists of drug within a nondeformable matrix; the use of nondeformable products in known stricture/narrowing of GI tract associated with symptoms of obstruction. Abrupt withdrawal may cause rebound angina in CAD.